Provided is a composition, including: an aqueous suspension, comprising: a first plurality of active ingredients, and one or more nanoparticles, wherein: the one or more nanoparticles encapsulate a second plurality of active ingredients; the second plurality of active ingredients are insoluble in the aqueous suspension; the one or more nanoparticles solubilize the second plurality of active ingredients in the aqueous suspension; and the one or more nanoparticles have a Z-average diameter between 50 to 950 nanometers.

This disclosure is directed to treatment of addictions and primary impulse-control disorders using phosphodiesterase 7 (PDE7) inhibitors, alone or in combination with other therapeutic agents.

This disclosure is directed to treatment of addictions and primary impulse-control disorders using phosphodiesterase 7 (PDE7) inhibitors, alone or in combination with other therapeutic agents.

A vaporization device includes a cartridge having a reservoir that holds a vaporizable material, a heating element, and a wicking element that can draw the vaporizable material to the heating element to be vaporized. The vaporizer cartridge is configured for coupling to a vaporizer device body and containing a vaporizable material. Various embodiments of the vaporizer cartridge are described that include an organic bifunctional wick-heater assembly using porous organic-based material. Related systems, methods, and articles of manufacture are also described.

A vaporization device includes a cartridge having a reservoir that holds a vaporizable material, a heating element, and a wicking element that can draw the vaporizable material to the heating element to be vaporized. The vaporizer cartridge is configured for coupling to a vaporizer device body and containing a vaporizable material. Various embodiments of the vaporizer cartridge are described that include an organic bifunctional wick-heater assembly using porous organic-based material. Related systems, methods, and articles of manufacture are also described.

The invention relates to a nicotine chewing gum giving an immediate release and uptake of nicotine as well as an extended release and uptake of nicotine as well as describing suitable manufacturing processes for such chewing gum formulations and the use of the chewing gum for the treatment of a human being suffering from cravings from tobacco and/or e-cigarette dependency.

The invention relates to a nicotine chewing gum giving an immediate release and uptake of nicotine as well as an extended release and uptake of nicotine as well as describing suitable manufacturing processes for such chewing gum formulations and the use of the chewing gum for the treatment of a human being suffering from cravings from tobacco and/or e-cigarette dependency.

This invention relates to a nicotine chewing gum giving an immediate release and uptake of nicotine and an extended release and uptake of nicotine as well as describing suitable manufacturing processes for such chewing gum formulations and the use of the chewing gum for the treatment of a human being suffering from cravings from tobacco and/or e-cigarette dependency.

This invention relates to a nicotine chewing gum giving an immediate release and uptake of nicotine and an extended release and uptake of nicotine as well as describing suitable manufacturing processes for such chewing gum formulations and the use of the chewing gum for the treatment of a human being suffering from cravings from tobacco and/or e-cigarette dependency.

A carbonated liquid nicotine formulation for an aerosol-generating system is provided, the carbonated liquid nicotine formulation including: at least one of water and one or more water-miscible solvents, the carbonated liquid formulation having an ethanol content of less than 1 percent by weight, a nicotine content of greater than or equal to 0.25 percent by weight, and a carbon dioxide content of greater than or equal to 0.5 percent by weight. A cartridge for an aerosol-generating system, and an aerosol-generating system, are also provided.